Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients

2022 ◽  
Author(s):  
Bryan Chong ◽  
Rachel Sze Jen Goh ◽  
Gwyneth Kong ◽  
Faith Ruo En Sim ◽  
Chen Han Ng ◽  
...  
Keyword(s):  
Systematic Review ◽  
Bayesian Network ◽  
Antiplatelet Therapy ◽  
Randomized Trials ◽  
Dual Antiplatelet Therapy ◽  
Meta Analysis ◽  
Drug Eluting Stents ◽  
Short Term ◽  
Durable Polymer ◽  
Drug Eluting

scholarly journals AN UPDATE META-ANALYSIS OF RANDOMIZED TRIALS COMPARING SHORT-TERM AND LONG-TERM DUAL ANTIPLATELET THERAPY FOLLOWING DRUG-ELUTING STENTS

2015 ◽  
Vol 65 (10) ◽  
pp. A1639
Author(s):  
Rahman Shah ◽  
Suzanne Stevens ◽  
Raza Askari ◽  
Mohamed Morsey ◽  
Adam Mizeracki ◽  
...  
Keyword(s):  
Antiplatelet Therapy ◽  
Randomized Trials ◽  
Dual Antiplatelet Therapy ◽  
Meta Analysis ◽  
Drug Eluting Stents ◽  
Short Term ◽  
Drug Eluting

scholarly journals Clinical Outcomes of Very Short Term Dual Antiplatelet Therapy in Patients With or Without Diabetes Undergoing Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

2021 ◽  
Vol 8 ◽  
Author(s):  
Xi-Ying Liang ◽  
Yan Li ◽  
Xuan Qiao ◽  
Wen-Jiao Zhang ◽  
Zhi-Lu Wang
Keyword(s):  
Systematic Review ◽  
Clinical Outcomes ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Meta Analysis ◽  
Drug Eluting Stents ◽  
Minor Bleeding ◽  
Short Term ◽  
Patients With Diabetes ◽  
Drug Eluting

Background: Patients with diabetes represent 20–30% of the population considered for percutaneous coronary intervention (PCI) and associate with more deleterious clinical outcome, which requires the optimal strategy of dual antiplatelet therapy (DAPT). The meta-analysis aims to compare clinical outcomes between very short (1–3 months) and standard (12 months) DAPT after implanting the second-generation drug-eluting stents in patients with or without diabetes following PCI.Methods and Analysis: PubMed, Embase, Web of Science, Ovid, Cochrane Library, and ClinicalTrials.gov were searched for studies comparing the very short term and standard DAPT in patients with or without diabetes following PCI. Risk ratio with 95% confidence intervals was used to evaluate the pooled effect of discontinuous variables, and the pooled analyses were performed with RevMan 5.3 and Stata SE 14.0 software.Results: A total of 38,864 patients were randomized to the very short term DAPT (N = 19,423) vs. standard DAPT (N = 19,441). Among them, 11,476 patients were diabetes and 27,388 patients were non-diabetes. The primary outcome of the net adverse clinical event (NACE) was significantly lower in diabetic patients with very short term DAPT (risk ratio 0.72, 95% CI 0.60–0.88, p = 0.0009). The same result was also found in the major cardiac or cerebrovascular events (MACCEs) (0.87, 0.78–0.98, p = 0.03). The risk of major or minor bleeding was significantly reduced in very short term DAPT regardless of the diabetes statue (0.69, 0.52–0.93, p = 0.01 in the diabetic group, and 0.50, 0.39–0.63, p <0.0001 in the non-diabetic group). There was no statistical difference in the incidence of major bleeding, all-cause death, cardiac death, myocardial infarction, definite or probable stent thrombosis, and stroke between the very short term DAPT (1–3 months) and standard DAPT (12 months) in patients with or without diabetes.Conclusion: The very short term DAPT can significantly reduce the risk of the NACE and MACCE in patients with diabetes compared to standard DAPT. Meanwhile, the very short term DAPT can also reduce the incidence of major and minor bleeding without increasing the risk of ischemia in patients with or without diabetes (Registered by PROSPERO, CRD42020192133).Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, Identifier: CRD42020192133.

scholarly journals Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials

2015 ◽  
Vol 33 (5) ◽  
pp. 253-263 ◽  
Author(s):  
Elsayed Abo-salem ◽  
Said Alsidawi ◽  
Hina Jamali ◽  
Mohamed Effat ◽  
Tarek Helmy
Keyword(s):  
Antiplatelet Therapy ◽  
Randomized Trials ◽  
Dual Antiplatelet Therapy ◽  
Meta Analysis ◽  
Drug Eluting Stents ◽  
Optimal Duration ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document